Company news

Heron Therapeutics, Inc. news in 2025

Heron Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)

December 3, 2025

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

November 3, 2025

Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

October 28, 2025

Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

October 20, 2025

Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value

August 14, 2025

Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025

August 7, 2025

Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress

August 7, 2025

Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile

August 7, 2025

Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025

July 27, 2025

Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations

May 5, 2025

Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

May 5, 2025

Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

April 27, 2025

Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025

April 21, 2025

Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates

February 26, 2025

Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025

February 12, 2025

Calls in 2025

Decks in 2025